| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
BWA-522 intermediate-1 targets cereblon (CRBN), which is a substrate receptor for an E3 ubiquitin ligase complex. As a CRBN ligand, it binds to CRBN and can recruit the E3 ligase machinery to a protein of interest when conjugated to a target-binding ligand. In the context of the final PROTAC molecule BWA-522, this CRBN-binding moiety is linked to an androgen receptor (AR) ligand. This allows BWA-522 to bring the AR protein into proximity with the CRBN E3 ligase, leading to AR ubiquitination and degradation. BWA-522 intermediate-1 itself is a building block that provides the CRBN-binding function in the PROTAC.
|
|---|---|
| ln Vitro |
In vitro activity of BWA-522 intermediate-1 is not characterized as a pharmacological agent, as it is a synthetic intermediate. Its primary in vitro application is in the chemical synthesis of BWA-522. The compound contains a cereblon-binding moiety. The final PROTAC molecule, BWA-522, is then tested for its ability to degrade AR-FL and AR-V7. BWA-522 intermediate-1 itself is not typically evaluated for biological activity.
|
| ln Vivo |
In vivo activity is not applicable to BWA-522 intermediate-1. BWA-522, the PROTAC synthesized from this intermediate, is orally active and has significant degradation effects on AR-FL and AR-V7. However, BWA-522 intermediate-1 itself is not administered as a drug.
|
| Enzyme Assay |
BWA-522 intermediate-1 is characterized by analytical techniques such as HPLC, NMR, and mass spectrometry to confirm identity and purity. Its cereblon-binding activity is typically assessed in the context of the final PROTAC molecule.
|
| Cell Assay |
BWA-522 intermediate-1 is not used in cell-based assays. The final PROTAC molecule, BWA-522, is evaluated in cell-based assays for its ability to degrade androgen receptor and inhibit prostate cancer cell growth.
|
| Animal Protocol |
BWA-522 intermediate-1 is not used in animal studies. BWA-522 is evaluated in vivo.
|
| ADME/Pharmacokinetics |
BWA-522 intermediate-1 has a molecular weight of 369.37. It is a research chemical and its pharmacokinetic properties are not relevant as it is not a drug.
|
| References | |
| Additional Infomation |
BWA-522 intermediate-1 is a research-grade cereblon ligand used as a building block for the PROTAC degrader BWA-522. BWA-522 is an orally active PROTAC that degrades the androgen receptor AR-FL and AR-V7. BWA-522 intermediate-1 has not entered clinical trials and is not approved for any therapeutic indication. Its mechanism of action is indirect: when incorporated into BWA-522, it enables the degradation of androgen receptor. The compound is available for research purposes.
|
| Molecular Formula |
C19H19N3O5
|
|---|---|
| Molecular Weight |
369.371264696121
|
| Exact Mass |
369.132
|
| CAS # |
2241315-66-0
|
| PubChem CID |
135167727
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
685
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)N4CCC(CC4)C=O
|
| InChi Key |
TXZFWPHJZKOMQY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H19N3O5/c23-10-11-5-7-21(8-6-11)12-1-2-13-14(9-12)19(27)22(18(13)26)15-3-4-16(24)20-17(15)25/h1-2,9-11,15H,3-8H2,(H,20,24,25)
|
| Chemical Name |
1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidine-4-carbaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7073 mL | 13.5366 mL | 27.0731 mL | |
| 5 mM | 0.5415 mL | 2.7073 mL | 5.4146 mL | |
| 10 mM | 0.2707 mL | 1.3537 mL | 2.7073 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
